Moberg Pharma AB (publ) logo

Moberg Pharma AB (publ) (MBGPF)

Market Closed
7 Aug, 20:00
OTC PINK OTC PINK
$
1. 10
0
0%
$
100.66M Market Cap
- P/E Ratio
- Div Yield
5,000 Volume
- Eps
$ 1.1
Previous Close
Add Transaction
Day Range
1.1 1.1
Year Range
0.82 1.2
Want to track MBGPF and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

MBGPF closed Friday higher at $1.1, an increase of 0% from Thursday's close, completing a monthly increase of 0% or $0. Over the past 12 months, MBGPF stock gained 4.7619%.
MBGPF is not paying dividends to its shareholders.
The last earnings report, released on May 12, 2026, exceeded the consensus estimates by 0%. On average, the company has fell short of earnings expectations by -0.0871%, based on the last three reports.
Moberg Pharma AB (publ) has completed 1 stock splits, with the recent split occurring on May 24, 2023.
The company's stock is traded on 7 different exchanges and in various currencies, with the primary listing on XSTO (SEK).

MBGPF Chart

Moberg Pharma AB (publ) (MBGPF) FAQ

What is the stock price today?

The current price is $1.10.

On which exchange is it traded?

Moberg Pharma AB (publ) is listed on OTC PINK.

What is its stock symbol?

The ticker symbol is MBGPF.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 100.66M.

Has Moberg Pharma AB (publ) ever had a stock split?

Moberg Pharma AB (publ) had 1 splits and the recent split was on May 24, 2023.

Moberg Pharma AB (publ) Profile

Specialty Retail Industry
Consumer Discretionary Sector
Dr. Jonas Ekblom Ph.D. CEO
OTC PINK Exchange
SE0003613090 ISIN
DE Country
5 Employees
- Last Dividend
- Last Split
- IPO Date

Overview

Moberg Pharma AB (publ) operates as a pharmaceutical company with a global reach, focusing on the development and commercialization of medical products. Originally known as Moberg Derma AB (publ), the company underwent a name change in May 2013, signaling a broader focus within the pharmaceutical industry. Since its foundation in 2006, Moberg Pharma has been dedicated to addressing complex medical conditions, with its headquarters located in Bromma, Sweden. The company has successfully positioned itself in both European and international markets, including the United States, by emphasizing research, development, and commercialization of novel treatments.

Products and Services

  • MOB-015
  • A leading product in Moberg Pharma’s portfolio, MOB-015, has reached a pivotal stage in its development. This innovative treatment for nail fungus has successfully completed Phase III clinical trials, marking a significant milestone towards offering patients a new, effective solution for this common but challenging condition. MOB-015’s progress underlines Moberg Pharma AB's commitment to advancing dermatological care through rigorous research and development.

Contact Information

Address: Gustavslundsvägen 42, Bromma, Sweden, 167 51
Phone: 46 8 52 23 07 00